*Press releases are taken from the company websites.
*Titles may be translated independently.
*Please be aware that, since data is collected automatically, there is a possibility of omissions occurring.
*We would like to kindly inform you that we do not collect all press releases from companies.
| Ticker Code | Date | Title | Link |
|---|---|---|---|
| TSE:2269 | 10/14/2025 | Chocolate heralds winter!Add a sense of the season with a package featuring large snowflakes!“Melty Kiss” will be released sequentially from October 21st / Nationwide | https://www.meiji.co.jp/corporate/pressrelease/2025/10_08/ |
| TSE:2269 | 10/14/2025 | In response to strong matcha needs, the amount of matcha used has been increased by 1.8 times!“Tsujiri Oikoi Matcha Latte” now available in a container with a cap that is convenient to carry and enjoys the aroma when opened. Released on October 21, 2025 / | https://www.meiji.co.jp/corporate/pressrelease/2025/10_09/ |
| TSE:4188 | 10/14/2025 | Application for additional indication for generalized myasthenia gravis in Japan for anti-CD19 monoclonal antibody preparation “YupriznaⓇ Intravenous Infusion 100mg” | https://www.mt-pharma.co.jp/news/2025/MTPC251014.html |
| TSE:4506 | 10/14/2025 | Novo Nordisk Pharma and Sumitomo Pharma announce the signing of a promotional partnership agreement for the obesity treatment drug "Ugobi Subcutaneous Injection" in Japan | https://www.sumitomo-pharma.co.jp/news/20251014-2.html |
| TSE:4506 | 10/14/2025 | Announcement of the latest clinical data presentation regarding the anticancer drug enzomenib (DSP-5336) under development at the Japanese Society of Hematology (JSH) 2025 | https://www.sumitomo-pharma.co.jp/news/20251014-1.html |
| TSE:4516 | 10/14/2025 | Announcement of results of up to 3.5 years of administration of brogidirsen (NS-089/NCNP-02), a treatment for Duchenne muscular dystrophy, at the World Muscle Society | https://www.nippon-shinyaku.co.jp/news/news.php?id=3512 |
| TSE:4536 | 10/14/2025 | Santen engages in volunteer activities for “World Sight Day” with employees around the world —Responding to 167 calls from visually impaired users in 26 languages through the “Be My Eyes” app— | https://www.santen.com/ja/news/2025/2025_1/20251014 |
| PFE | 10/14/2025 | TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial | https://www.pfizer.com/news/press-release/press-release-detail/tukysa-combination-significantly-improves-progression-free |
| ABBV | 10/13/2025 | U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease | https://news.abbvie.com/2025-10-13-U-S-Food-and-Drug-Administration-FDA-Approves-Updated-Indication-Statement-for-RINVOQ-R-upadacitinib-for-the-Treatment-of-Inflammatory-Bowel-Disease |
| ABBV | 10/13/2025 | AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors | https://news.abbvie.com/2025-10-13-AbbVie-to-Present-New-Data-at-ESMO-2025-Reinforcing-Leadership-in-Advancing-Targeted-Therapies-for-Solid-Tumors |
| AZN | 10/13/2025 | AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO | https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2025/astrazeneca-furthers-ambition-to-redefine-cancer-care-with-first-data-from-four-major-pivotal-trials-at-esmo.html |
| BMY | 10/13/2025 | Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types | https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-to-Present-Data-at-ESMO-2025-Showcasing-Progress-of-Oncology-Portfolio-Across-Diverse-Tumor-Types/default.aspx |
| PFE | 10/13/2025 | Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025 | https://www.pfizer.com/news/press-release/press-release-detail/pfizer-highlight-advancements-respiratory-health-and |
| BIIB | 10/13/2025 | LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025” | https://investors.biogen.com/news-releases/news-release-details/leqembir-iqliktmlecanemab-irmb-subcutaneous-autoinjector-named |
| TSE:4507 | 10/10/2025 | Announcement by Torii Pharmaceutical regarding application for manufacturing and marketing approval in Japan (childhood atopic dermatitis) for the aromatic hydrocarbon receptor (AhR) modulator JTE-061 (Tapinarov) Cream | https://www.shionogi.com/jp/ja/news/2025/10/20251010.html |